CD24 Protein, Human, Recombinant (GST)

CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 850.00
500 μg	5 days	$ 3,390.00
1 mg	5 days	$ 5,670.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 850.00

500 μg

5 days

$ 3,390.00

1 mg

5 days

$ 5,670.00

Description

Species	Human
Expression System	E. coli
Tag	N-GST
Accession Number	P25063
Synonyms	CD 24, CD24 molecule, FLJ22950, FLJ43543, CD24A, MGC75043
Construction	Recombinant Human CD24 Protein is expressed from E.coli with GST at the N-Terminus. It contains Ser27-Gly59.[Accession \|P25063]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 31.6 kDa same as Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.